Dashboard
Manage Tickers

VSTMVerastem, Inc.

Nasdaq verastem.com


$ 10.86 $ 0.54 (5.21 %)    

Friday, 03-May-2024 15:59:44 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 10.9
$ 11.03
$ 0.00 x 0
$ 0.00 x 0
$ 10.67 - $ 11.03
$ 4.68 - $ 15.18
104,256
na
240.39M
$ 1.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-14-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 03-28-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-02-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-18-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-11-2020 12-31-2019 10-K
18 10-30-2019 09-30-2019 10-Q
19 08-01-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-12-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-03-2018 03-31-2018 10-Q
25 03-13-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-08-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 03-23-2017 12-31-2016 10-K
30 11-07-2016 09-30-2016 10-Q
31 08-08-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 03-03-2016 12-31-2015 10-K
34 11-09-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-10-2015 12-31-2014 10-K
38 10-30-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

verastem-oncology-partner-genfleet-therapeutics-unveils-latest-research-findings-of-gfh375-at-aacr-annual-meeting
Verastem Oncology Partner GenFleet Therape...
04/09/2024 11:16:20

hc-wainwright--co-reiterates-buy-on-verastem-maintains-175-price-target
HC Wainwright & Co. Reiterates Buy on Vera...
03/19/2024 10:38:51

HC Wainwright & Co. analyst Sean Lee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $17.5 price target.

rbc-capital-reiterates-outperform-on-verastem-maintains-32-price-target
RBC Capital Reiterates Outperform on Veras...
03/15/2024 16:46:49

RBC Capital analyst Gregory Renza reiterates Verastem (NASDAQ:VSTM) with a Outperform and maintains $32 price target.

recap-verastem-q4-earnings
Recap: Verastem Q4 Earnings
03/14/2024 21:55:07

verastem-q4-2023-adj-eps-110-misses-062-estimate
Verastem Q4 2023 Adj EPS $(1.10) Misses $(...
03/14/2024 20:17:20

Verastem (NASDAQ:VSTM) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.62) by...

verastem-oncology-announces-multiple-oral-presentations-at-society-of-gynecologic-oncology-2024-annual-meeting-on-womens-cancer
Verastem Oncology Announces Multiple Oral ...
03/11/2024 11:48:09

Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib ...

verastem-oncology-secures-fda-orphan-drug-designation-for-avutometinib-alone-or-in-combination-with-defactinib-in-recurrent-low-grade-serous-ovarian-cancer
Verastem Oncology Secures FDA Orphan Drug ...
03/05/2024 22:29:24

The company said it remains on track to begin submission of an NDA to the FDA for Accelerated Approval of this combination in t...

verastem-oncology-announces-preclinical-presentations-for-new-oral-g12d-inhibitor-and-for-avutometinib-and-defactinib-combination-as-a-backbone-of-therapy-for-rasmapk-driven-cancers-at-aacr-annual-meeting-2024
Verastem Oncology Announces Preclinical Pr...
03/05/2024 21:37:21

 GFH375 (VS-7375), a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, demonstrated potent anti-tumor activity in panc...

why-big-lots-shares-are-trading-lower-by-around-31-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Big Lots Shares Are Trading Lower By A...
02/12/2024 18:07:28

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarte...

verastem-oncology-outlines-key-2024-strategic-priorities-and-upcoming-catalysts-for-advancing-avutometinib-and-defactinib-and-broader-pipeline-in-ras-pathway-driven-cancers
Verastem Oncology Outlines Key 2024 Strate...
01/29/2024 12:04:03

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, tod...

verastem-oncology-granted-fast-track-designation-for-combination-of-avutometinib-and-sotorasib-for-the-treatment-of-kras-g12c-mutant-non-small-cell-lung-cancer
Verastem Oncology Granted Fast Track Desig...
01/18/2024 21:00:53

Ongoing RAMP 203 Trial Assessing a More Complete Vertical Blockade with RAF/MEK and KRAS G12C Inhibition Along RAS Pathway to I...

verastem-oncology-announced-a-potential-kras-g12d-oral-inhibitor-as-the-lead-program-of-its-discovery-and-development-collaboration-with-genfleet-therapeutics-investigational-new-drug-submission-planned-for-gfh375vs-7375-in-h1-2024
Verastem Oncology Announced A Potential KR...
12/18/2023 12:50:41

verastem-oncology-has-initiated-its-international-confirmatory-phase-3-ramp-301-trial-of-avutometinib-and-defactinib-combo-versus-standard-chemotherapy-or-hormonal-therapy-for-recurrent-low-grade-serous-ovarian-cancer
Verastem Oncology Has Initiated Its Intern...
12/13/2023 12:02:28

btig-assumes-verastem-at-buy-announces-price-target-of-27
BTIG Assumes Verastem at Buy, Announces Pr...
11/21/2023 13:36:01

BTIG analyst Justin Zelin assumes Verastem (NASDAQ:VSTM) with a Buy rating and announces Price Target of $27.

where-verastem-stands-with-analysts
Where Verastem Stands With Analysts
11/15/2023 17:01:01

truist-securities-maintains-buy-on-verastem-lowers-price-target-to-34
Truist Securities Maintains Buy on Veraste...
11/15/2023 16:56:13

Truist Securities analyst Srikripa Devarakonda maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from ...

verastem-q3-eps-071-beats-084-estimate
Verastem Q3 EPS $(0.71) Beats $(0.84) Esti...
11/08/2023 22:28:50

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.84) by 1...

verastem-oncology-strengthens-executive-leadership-team-with-key-appointments-dan-calkins-promoted-to-chief-financial-officer-from-vice-president-of-finance
Verastem Oncology Strengthens Executive Le...
10/26/2023 20:47:03

Mike Crowther Appointed Chief Commercial and Business Strategy OfficerDavid Mitchell Appointed Senior Vice President, Head of R...

reported-earlier-verastem-oncology-announced-initial-results-of-ramp-203-trial-of-avutometinib-and-lumakras-in-kras-g12c-mutant-non-small-cell-lung-cancer
Reported Earlier, Verastem Oncology Announ...
10/16/2023 06:32:42

b-riley-securities-reiterates-buy-on-verastem-maintains-21-price-target
B. Riley Securities Reiterates Buy on Vera...
09/29/2023 14:01:02

B. Riley Securities analyst Kalpit Patel reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $21 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION